Issue |
Section |
Title |
File |
Vol 19, No 1 (2020) |
ORIGINAL ARTICLES |
Non-invasive prediction of an unfavorable histological variant in patients with neuroblastic tumors using the quantitative and semiquantitative assessment of ¹²³I-MIBG uptake |
 (Rus)
|
Vol 20, No 4 (2021) |
ORIGINAL ARTICLES |
The value of single-photon emission computed tomography combined with computed tomography imaging in ¹²³I-Metaiodobenzylguanidine scintigraphy in children with neuroblastoma |
 (Rus)
|
Vol 19, No 4 (2020) |
ПЕРЕДОВАЯ СТАТЬЯ |
Pharmacokinetics of 13-cis-Retinoic acid in high-risk neuroblastoma patients |
 (Rus)
|
Vol 19, No 4 (2020) |
ORIGINAL ARTICLES |
Bilateral adrenal neuroblastoma: clinical presentation, diagnostic and therapeutic approaches, treatment results |
 (Rus)
|
Vol 21, No 1 (2022) |
LITERATURE REVIEW |
Predictive value of metabolic parameters of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography for survival rates of children with lymphoma (a metaanalysis and literature review) |
 (Rus)
|
Vol 21, No 2 (2022) |
LITERATURE REVIEW |
The impact of response to induction chemotherapy on the event-free and overall survival in patients with high-risk neuroblastoma: a systematic review and meta-analysis |
 (Rus)
|
Vol 22, No 2 (2023) |
ORIGINAL ARTICLES |
The results of therapy in patients with high-risk neuroblastoma: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology |
 (Rus)
|
Vol 22, No 4 (2023) |
LITERATURE REVIEW |
The diagnostic roles of fused 18F-fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphy in children and young adults with bone sarcomas: a systematic review and meta-analysis |
 (Rus)
|
Vol 23, No 1 (2024) |
ORIGINAL ARTICLES |
Visual and quantitative assessment of interim 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in children with Hodgkin lymphoma |
 (Rus)
|
Vol 23, No 1 (2024) |
ORIGINAL ARTICLES |
Tolerability and toxicity of induction chemoimmunotherapy with dinutuximab beta in newly diagnosed patients with high-risk neuroblastoma |
 (Rus)
|
Vol 23, No 3 (2024) |
ORIGINAL ARTICLES |
Second malignant neoplasms after neuroblastoma treatment: a single center experience |
 (Rus)
|